BIOLOGÍA MOLECULAR Y CELULAR EN HEMOPATÍAS
University of California Los Angeles
Los Ángeles, Estados UnidosPublicaciones en colaboración con investigadores/as de University of California Los Angeles (2)
2014
-
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477